1 recruiting. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Recruiting 1 |
Follow Yang Hong: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant SBRT Followed by Sintilimab Plus Chemotherapy for N3-Positive NSCLC Sintilimab, Paclitaxel, Carboplatin (AUC 5) - Locally Advanced Non-Small Cell Lung Cancer, Stage IIIb Non-small Cell Lung Cancer | Phase 2 | Recruiting | Yang Hong | 28 | 2025-12-31 | 2026-04-30 |
Carcinoma, Non-Small-Cell Lung (1)
Carboplatin (1) · Paclitaxel (1) · Pemetrexed (1) · Radiosurgery (1) · sintilimab (1)
China (1)